Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals stock surges 24.4% following positive late-stage clinical data for its lipid-lowering drug, Redemplo.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Arrowhead Pharmaceuticals experienced a significant share price increase of 24.4% on July 22, 2026. This movement follows the release of late-stage trial results for Redemplo, a drug designed to treat severe hypertriglyceridemia. Coverage indicates that Redemplo successfully reduces triglyceride levels and the associated risk of pancreatitis.
Financial and pharmaceutical outlets, including AlphaStreet, Seeking Alpha, Fierce Pharma, and Investor's Business Daily, report that this trial outcome has negatively impacted Ionis, a direct competitor in the lipid-lowering drug space. JP Morgan has responded to the data by maintaining an Overweight rating on Arrowhead Pharmaceuticals. Market observers are monitoring the competitive shift between Arrowhead and Ionis in the hypertriglyceridemia treatment market.
Coverage does not yet specify the long-term commercial timeline for Redemplo beyond the current trial results.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.
Quick answers
What caused the stock price movement for Arrowhead Pharmaceuticals?
The 24.4% surge followed the announcement of successful late-stage trial data for their drug, Redemplo.
How did Ionis respond to the news?
Coverage indicates that Ionis stock dropped following the release of the trial results for its competitor.
What is the primary function of Redemplo?
Redemplo is a lipid-lowering drug used to treat severe hypertriglyceridemia and reduce the risk of pancreatitis.
Coverage (8)
- ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval Yahoo Finance · 8h ago
- Arrowhead's Plozasiran Reduces Triglycerides, Pancreatitis Events in Phase 3 sHTG Trials BioPharm International · 8h ago
- ARWR Stock Climbs As EU Approval And Analyst Targets Heat Up StocksToTrade · 8h ago
- Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight AlphaStreet · 8h ago
- Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia Managed Healthcare Executive · 8h ago
- Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug Seeking Alpha · 8h ago
- Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data Fierce Pharma · 8h ago
- Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled Investor's Business Daily · 8h ago
Topics
Related trends
GE Vernova stock drops despite surging AI-driven orders as wind segment drags
GE Vernova stock falls as strong AI-driven power demand is offset by persistent weakness within the company's wind energy segment.
Exclusive | AMD and Anthropic Sign Major Chips-and-Investment Deal
Advanced Micro Devices and Anthropic have entered into a significant new partnership involving chips and capital investment.
Supermicro stock jumps on gross margin raise amid record $60 billion backlog
Super Micro Computer shares rise following reports of record-breaking order backlogs and higher-than-anticipated gross margins.
Supermicro shares surge 20% as robust margins, $60B backlog eclipse soft revenue
Supermicro stock experiences a significant rally as a record $60 billion backlog and improved margins outweigh reports of soft revenue.
Charles Schwab Earnings: Why Stock Is Falling Despite Faster Growth
Charles Schwab shares are sliding despite the company reporting record quarterly revenue and earnings that exceeded Wall Street estimates.
Netflix Fell 45% Over 12 Months But This Ratings House Sees A Doubling Share Price
Netflix stock faces contrasting market outlooks following a reported 45% decline over the past twelve months.